Clinical Trials

249 enrolled

Renal Pelvis and Ureter Urothelial Carcinoma

NCT05987241 2026-03-18

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

992 enrolled

Muscle Invasive Bladder Urothelial Carcinoma

NCT06780670 2026-03-16

PSMAcTION

443 enrolled

Prostatic Neoplasms

NCT07106762 2026-03-10

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

470 enrolled

Urinary Bladder Neoplasms

NCT05597878 2026-03-06

Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy

Phase 2/3 Suspended

100 enrolled

Agnosia, Prostatic Neoplasms

NCT07129993 2026-03-05

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

630 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07426055 2026-02-23

PRO-BOOST-LC

1,200 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT07426094 2026-02-23

PRO-BOOST-N

1,600 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT06225596 2026-02-17

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

956 enrolled

Urinary Bladder Neoplasms

NCT03070886 2026-01-14

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

612 enrolled

Stage I Prostate Adenocarcinoma AJCC v7

NCT03258320 2026-01-12

A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients

300 enrolled

Prostatic Neoplasms

NCT00117286 2025-12-18

Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer

57 enrolled 15 charts

Prostatic Neoplasms

NCT03701581 2025-12-17

4-aminopyridine Treatment for Nerve Injury

70 enrolled

Erectile Dysfunction, Prostatic Neoplasms

NCT07084909 2025-12-10

HARRIER

Phase 2/3 Withdrawn

Carcinoma, Renal Cell, Kidney Neoplasms

NCT06861192 2025-11-18

Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer

83 enrolled

Prostate CA

NCT03022825 2025-10-16

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

190 enrolled 1 FDA

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03772834 2025-10-10

Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer

200 enrolled

Prostatic Neoplasms

NCT07209878 2025-10-07

68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI

100 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT07198451 2025-09-30

GEM-IR-NMIBC

320 enrolled

Non-Muscle Invasive Bladder Neoplasms, Recurrence

NCT07156786 2025-09-19

N-Acetylcysteine Roles in Preserving Renal Function Measured by Urinary KIM-1 (Kidney Injury Molecule-1) and Serum Creatinine on Cancer Patients With Cisplatin Based Chemotherapy: A Randomized Placebo-Controlled Trial

72 enrolled

Neoplasms, Acute Kidney Injury

NCT06124976 2025-09-15

Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma

70 enrolled

Urothelial Carcinoma of the Renal Pelvis and Ureter

NCT03348670 2025-08-17

Drugs-SNPs

600 enrolled

Neoplasms, Prostatic Neoplasms

NCT05137561 2025-08-07

PROBIOP

217 enrolled

Prostatic Neoplasms

NCT06537154 2025-07-30

NEO-BLAST

688 enrolled

Urinary Bladder Neoplasms

NCT05920343 2025-07-10

PREVENT-GU

Classical hematologyGenitourinary

120 enrolled

Urogenital Neoplasms, Urologic Neoplasms, Venous Thromboembolism

NCT06879145 2025-06-18

Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)

840 enrolled

Muscular Invasive Bladder Cancer (MIBC)

NCT06972511 2025-05-15

Maximal Tumor Eradication for Oligometastatic Prostate Cancer

120 enrolled

Oligometastatic Prostate Cancer

NCT03706365 2025-04-20

CYCLONE 2

393 enrolled 23 charts

Prostatic Neoplasms

NCT03822845 2025-04-17

Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer

6 enrolled 8 charts

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06493552 2025-04-03

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

700 enrolled

Carcinoma, Transitional Cell

NCT03525288 2025-03-13

PSMA-PETgRT

130 enrolled

Prostatic Neoplasms

NCT06861166 2025-03-06

Clinical Study of Geranium Wilfordii Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer

95 enrolled

Prostate CA

NCT02984124 2025-02-18

CHART

182 enrolled

Kidney Failure, Chronic

NCT05381103 2025-01-31

PSMA-PET to Guide Prostatectomy

288 enrolled

Prostatic Neoplasms

NCT02685397 2024-12-04

PCS IX

102 enrolled

Castration-resistant Prostate Cancer Patients with Oligometastases

NCT06601205 2024-09-19

2F

125 enrolled

Prostatic Neoplasms, Prostatic Intraepithelial Neoplasia

NCT03389451 2024-07-12

68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer

30 enrolled 10 charts

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT05627752 2024-02-28

Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage

Phase 2/3 Unknown

120 enrolled

Prostatic Neoplasms

NCT06282588 2024-02-28

THUNDER

493 enrolled

Prostatic Neoplasms

NCT03388346 2024-02-15

68Ga PSMA in Preprostatectomy Patients

22 enrolled 15 charts

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT04242017 2023-12-13

LOBSTER

394 enrolled

Phase 2/3 Enrolling by invitation

Prostatic Neoplasms

NCT03459820 2023-11-27

Prostate Cancer Patient Management With 18F-DCFPyL PET/CT

1,500 enrolled

Prostatic Neoplasms

NCT00584532 2023-11-24

GCP

66 enrolled

Neoplasms, Prostatic Neoplasms

NCT04654338 2023-06-27

EARTH

30 enrolled

Prostatic Neoplasms

NCT05841992 2023-05-03

Al18F-PSMA-617 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients

Phase 2/3 Unknown

100 enrolled

Prostatic Neoplasms

NCT01907009 2023-04-19

MEL-CAP

Phase 2/3 Terminated

29 enrolled

Castrate Resistant Prostate Cancer

NCT00268476 2023-04-18

STAMPEDE

11,992 enrolled

Prostatic Neoplasms

NCT02624518 2023-04-10

68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer

122 enrolled 8 charts

Prostate Adenocarcinoma

NCT03103152 2023-03-29

PROVENT

104 enrolled 14 charts

Prostatic Neoplasms

NCT04627896 2023-02-02

Targeted Microwave Focal Therapy

11 enrolled